Issue 99

biocase

Psychedelic Healthcare in Brazil, with Biocase’s CSO Dr Cesar Camara and CEO Sergio Fadul

Earlier this month Biocase secured a licence from the Brazilian Ministry of Education, to train psychedelic-assisted therapists at Alma Viva Institute in São Paulo City.

It was the first in Brazil to receive such a licence, and also the first to receive approval to conduct clinical trials with psilocybin.

Biocase’s postgraduate training will run alongside its Phase II trials with psilocybe cubensis, for the treatment of end-of-life anxiety in cancer patients.

READ MORE

PSYCHIATRISTS APPEAL REJECTION OF SPRAVATO

The National Institute for Health and Care Excellence said the esketamine nasal spray is too expensive for the NHS.

Read More

LONDON AS EUROPE'S CAPITAL FOR PSYCHEDELIC SCIENCE

The UK is home to leading academic institutions, publicly listed companies and emerging clinical research organisations.

Read More

BUSINESS AND INVESTMENT

Havn Life Sciences unable to meet financial obligations.

Inside Beckley Foundation’s US$7,000 luxury psilocybin retreat.

MHRA approves Psyence’s Phase II psilocybin study.

Investing in non-drug psychedelic healthcare startups.

Small Pharma completes enrolment for Phase II DMT study.

Numinus providing ketamine-assisted therapy in Toronto.

FDA approves Xpira’s Phase II psilocybin study in anorexia.

Psilera receives patent for transdermal patch.

The Psychedelics as Medicine Report provides market insights from industry experts.

With over 60,000 downloads, the flagship publication contains proprietary data for regulators, researchers and investors to make informed decisions.

Previous partners include atai Life Sciences, COMPASS Pathways, Cybin and Filament Health.

To be included in the fourth edition and to discuss future events, please contact [email protected]

CONTACT FORM

SCIENCE AND RESEARCH

NZ$50m research facility for psychedelic medicine opens in Auckland.

Ketamine in the treatment of levodopa-induced dyskinesia.

REGULATION AND LEGISLATION

Measures for state-wide regulation advance in Michigan.

Native American Church leaders ask congress for peyote preservation fund.

ARTICLES OF INTEREST

Current approved therapies to treat major depressive disorder.

A history of psychedelic research in Canada.